195 related articles for article (PubMed ID: 33569430)
1. Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity.
Zhong LH; Wu ZD; Wang JC; Wu ZZ; Chen FF; Zhu WF; Chen YP; Chen G
Ann Transl Med; 2021 Jan; 9(2):128. PubMed ID: 33569430
[TBL] [Abstract][Full Text] [Related]
2. Molecular Screening in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: Anaplastic Lymphoma Kinase Analysis, Next-Generation Sequencing Fusion Gene Detection, and T-Cell Receptor Immunoprofiling.
Kalinova M; Mrhalova M; Kabickova E; Svaton M; Skotnicova A; Prouzova Z; Krenova Z; Kolenova A; Divoka M; Fronkova E; Kodet R
Mod Pathol; 2024 Mar; 37(3):100428. PubMed ID: 38266918
[TBL] [Abstract][Full Text] [Related]
3. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
5. The biology and management of systemic anaplastic large cell lymphoma.
Hapgood G; Savage KJ
Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
[TBL] [Abstract][Full Text] [Related]
6. (18)F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase.
Lee DY; Lee JJ; Kim JY; Park SH; Chae SY; Kim S; Yoon DH; Suh C; Huh J; Ryu JS
Nucl Med Mol Imaging; 2013 Dec; 47(4):249-56. PubMed ID: 24900120
[TBL] [Abstract][Full Text] [Related]
7. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
Subbiah V; Kuravi S; Ganguly S; Welch DR; Vivian CJ; Mushtaq MU; Hegde A; Iyer S; Behrang A; Ali SM; Madison RW; Venstrom JM; Jensen RA; McGuirk JP; Amin HM; Balusu R
ESMO Open; 2021 Aug; 6(4):100172. PubMed ID: 34242968
[TBL] [Abstract][Full Text] [Related]
8. ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas.
Pina-Oviedo S; Ortiz-Hidalgo C; Carballo-Zarate AA; Zarate-Osorno A
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572893
[TBL] [Abstract][Full Text] [Related]
9. Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile.
Kwatra KS; Paul PAM; Calton N; John JM; Cotelingam JD
South Asian J Cancer; 2017; 6(3):129-131. PubMed ID: 28975123
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A; Soma L
Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
[TBL] [Abstract][Full Text] [Related]
11. The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL).
Montes-Mojarro IA; Steinhilber J; Bonzheim I; Quintanilla-Martinez L; Fend F
Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29617304
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Capability of Next-Generation Sequencing Fusion Analysis in Identifying a Rare CASE of
Agarwal I; Sabatini L; Alikhan MB
Front Oncol; 2020; 10():730. PubMed ID: 32457846
[No Abstract] [Full Text] [Related]
13. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma.
Boi M; Rinaldi A; Kwee I; Bonetti P; Todaro M; Tabbò F; Piva R; Rancoita PM; Matolcsy A; Timar B; Tousseyn T; Rodríguez-Pinilla SM; Piris MA; Beà S; Campo E; Bhagat G; Swerdlow SH; Rosenwald A; Ponzoni M; Young KH; Piccaluga PP; Dummer R; Pileri S; Zucca E; Inghirami G; Bertoni F
Blood; 2013 Oct; 122(15):2683-93. PubMed ID: 24004669
[TBL] [Abstract][Full Text] [Related]
14. Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.
Wang X; Wu J; Zhang M
Hematology; 2019 Dec; 24(1):440-445. PubMed ID: 31072226
[TBL] [Abstract][Full Text] [Related]
15. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
Stein H; Foss HD; Dürkop H; Marafioti T; Delsol G; Pulford K; Pileri S; Falini B
Blood; 2000 Dec; 96(12):3681-95. PubMed ID: 11090048
[TBL] [Abstract][Full Text] [Related]
16. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
[TBL] [Abstract][Full Text] [Related]
17. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients.
Wang YF; Yang YL; Gao ZF; Zhou CJ; Gregg X; Shi YF; Wang J; Yang XF; Ke XY
J Hematol Oncol; 2012 Jul; 5():38. PubMed ID: 22769020
[TBL] [Abstract][Full Text] [Related]
18. The expressions of MUM-1 and Bcl-6 in ALK-negative systemic anaplastic large cell lymphoma with skin involvement and primary cutaneous anaplastic large cell lymphoma.
Cho YR; Seo JW; Oh SY; Pak MK; Kim KH
Int J Clin Exp Pathol; 2020; 13(7):1682-1687. PubMed ID: 32782689
[TBL] [Abstract][Full Text] [Related]
19. ALK-Negative Anaplastic Large Cell Lymphoma (ALCL): Prognostic Implications of Molecular Subtyping and JAK-STAT Pathway.
Parkhi M; Bal A; Das A; Kashyap D; Bhardwaj S; Prakash G; Malhotra P
Appl Immunohistochem Mol Morphol; 2021 Oct; 29(9):648-656. PubMed ID: 33901030
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
